PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
3.86%
Positive operating income growth while GNPX is negative. John Neff might view this as a competitive edge in operations.
-1.47%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
12.77%
EPS growth under 50% of GNPX's 54.42%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.49%
Diluted EPS growth under 50% of GNPX's 54.20%. Michael Burry would worry about an eroding competitive position or excessive dilution.
16.41%
Share reduction more than 1.5x GNPX's 204.72%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
17.29%
Diluted share reduction more than 1.5x GNPX's 203.13%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
23.86%
Positive OCF growth while GNPX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
23.57%
Positive FCF growth while GNPX is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19211.55%
Negative 5Y OCF/share CAGR while GNPX is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.46%
Negative 3Y OCF/share CAGR while GNPX stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Negative 10Y net income/share CAGR while GNPX is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-50766.69%
Negative 5Y net income/share CAGR while GNPX is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
48.21%
3Y net income/share CAGR of 48.21% while GNPX is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
19776.75%
Equity/share CAGR of 19776.75% while GNPX is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
4394.26%
Equity/share CAGR of 4394.26% while GNPX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
625.15%
Equity/share CAGR of 625.15% while GNPX is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Asset growth of 30.51% while GNPX is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
8.68%
BV/share growth of 8.68% while GNPX is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Our R&D shrinks while GNPX invests at 43.87%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
108.24%
SG&A growth well above GNPX's 38.08%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.